Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (17812)	1/15/1999 5:58:00 PM
From: VLAD	Respond to of 23519

Frost, Vivus has had a fairly consistent history of ignoring their attackers and thus not defending the stock's price. Actually, as I see it this article can be used by Vivus as a platform for free publicity. By responding to it in an educational manner, Vivus can point out that although Viagra has hurt MUSE sales due to its incredible media exposure, it has not rendered it obsolete. Come to think of it, the article called Vivus' research obsolete. Perhaps NF can point out gene therapy and how it will render Viagra obsolete in the organic vascular ED population. Vivus can either keep its nose in the dirt or get up and fight. This is a good example of the need for more effective IR. Stock holder's movement: latest count is 37 share holders representing 1,351,551. Come on all! If you have not joined please join up ASAP. Leland and Virgil are about tied with our total share count. We need at least 200,000 more shares to get a solid lead on them.

To: Frostman who wrote (17812)	1/15/1999 6:07:00 PM
From: VLAD	Respond to of 23519

Dr. S. Kaul (Cedar Sinai Medical Center) is going to give an one hour lecture titled, "Use of Viagra in Patients with Cardiovascular Disease" at the Southern California Region III Scientific Meeting on February 26, 1999. acponline.org Expect to see more and more lectures such as these which will warn doctors not to indiscriminately prescribe Viagra to the at risk group. I am fairly surprised that we have not yet seen a class action lawsuit filed against Pfizer. It's not a question of IF but WHEN.